Responsiveness of the Intermittent and Constant Osteoarthritis Pain (ICOAP) scale in a trial of duloxetine for treatment of osteoarthritis knee pain

Summary Objective To assess the change in the Intermittent and Constant Osteoarthritis Pain (ICOAP)-scale scores in patients taking duloxetine or placebo and to characterize the responsiveness of the ICOAP by comparing the effect size associated with its scales to effect sizes seen with other pain s...

Full description

Saved in:
Bibliographic Details
Published in:Osteoarthritis and cartilage 2013-05, Vol.21 (5), p.691-694
Main Authors: Risser, R.C, Hochberg, M.C, Gaynor, P.J, D’Souza, D.N, Frakes, E.P
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Analgesics, Non-Narcotic - therapeutic use
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Double-Blind Method
Drug Therapy, Combination
Duloxetine
Duloxetine Hydrochloride
Female
Humans
ICOAP
Knee
Male
Middle Aged
Osteoarthritis
Osteoarthritis, Knee - complications
Osteoarthritis, Knee - drug therapy
Pain
Pain - drug therapy
Pain - etiology
Pain Measurement - methods
Responsiveness
Rheumatology
Thiophenes - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Objective To assess the change in the Intermittent and Constant Osteoarthritis Pain (ICOAP)-scale scores in patients taking duloxetine or placebo and to characterize the responsiveness of the ICOAP by comparing the effect size associated with its scales to effect sizes seen with other pain scales used in this study. Methods This was a secondary analysis of data from a 10-week, double-blind, randomized, flexible-dose, placebo-controlled trial that enrolled patients who had persistent moderate pain due to osteoarthritis (OA) of the knee, despite having received nonsteroidal anti-inflammatory drug (NSAID) therapy. The pain measures used in this study (focusing on the drug-placebo difference at week 8) were patient-rated pain severity, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), the Brief Pain Inventory (BPI), and the ICOAP. Results The mean difference between duloxetine and placebo at week 8 for patient-rated pain severity, the BPI average pain, WOMAC pain, and each ICOAP scale was statistically significant ( P  
ISSN:1063-4584
1522-9653
DOI:10.1016/j.joca.2013.02.007